吸入性糖皮质激素剂量与不良事件频率的关联
该观察性研究基于英国两个全国性数据库(Clinical Practice Research Datalink Aurum 和 GOLD),纳入成年哮喘患者,暴露为新发使用吸入性糖皮质激素(ICS),观察12个月内主要不良心血管事件(MACE)、心律失常、肺栓塞(PE)和肺炎。主要分析采用稳定逆概率治疗加权队列法,共纳入162,202例患者。结果显示,中剂量(201-599 μg/日)及以上与所有结局相关,≥600 μg/日时风险更高;低剂量无关联。作者结论为短期低剂量ICS无不良事件关联,中高日剂量与心血管事件、PE和肺炎风险升高相关但频率低,临床医生应遵循指南使用最低有效ICS剂量。
要点
- 在162,202例成年哮喘患者中,ICS日剂量201-599 μg与MACE(HR 2.63,95%CI 1.66-4.15)、心律失常(HR 2.21,95%CI 1.60-3.04)、PE(HR 2.10,95%CI 1.37-3.22)和肺炎(HR 2.25,95%CI 1.77-2.85)相关。
- ICS日剂量≥600 μg时风险进一步升高:MACE HR 4.63(95%CI 2.62-8.17)、心律失常HR 2.91(95%CI 1.72-4.91)、PE HR 3.32(95%CI 1.69-6.50)、肺炎HR 4.09(95%CI 2.98-5.60)。
- 低剂量ICS与上述不良事件无关联。
- 12个月ICS 201-599 μg的需害人数(NNH):MACE 473(95%CI 344-754)、心律失常567(95%CI 395-1,006)、PE 1,221(95%CI 744-3,388)、肺炎230(95%CI 177-327);
- 作者认为临床医生应遵循指南推荐,使用最低有效ICS剂量。
适用人群与场景
- 成年哮喘患者,来自英国两个全国性数据库(Clinical Practice Research Datalink Aurum 和 Clinical Practice Research Datalink GOLD)。
- 暴露为新发使用吸入性糖皮质激素(incident ICS),观察12个月内的结局。
研究设计与关键结果
- 研究类型:观察性研究(队列法主要分析,辅以巢式病例对照和自身对照病例系列),使用两个英国全国性数据库,主要队列162,202例。
- 主要分析采用稳定逆概率治疗加权平衡混杂,ICS作为分类和连续变量处理,绝对风险用加权灵活参数模型估计。
- 中剂量ICS(201-599 μg/日)与MACE(HR 2.63,95%CI 1.66-4.15)、心律失常(HR 2.21,95%CI 1.60-3.04)、PE(HR 2.10,95%CI 1.37-3.22)、肺炎(HR 2.25,95%CI 1.77-2.85)相关。
- 高剂量ICS(≥600 μg/日)与MACE(HR 4.63,95%CI 2.62-8.17)、心律失常(HR 2.91,95%CI 1.72-4.91)、PE(HR 3.32,95%CI 1.69-6.50)、肺炎(HR 4.09,95%CI 2.98-5.60)相关。
- 低剂量ICS与所有结局无关联。
- 12个月ICS 201-599 μg的NNH:MACE 473(95%CI 344-754)、心律失常567(95%CI 395-1,006)、PE 1,221(95%CI 744-3,388)、肺炎230(95%CI 177-327)。
- 12个月ICS ≥600 μg的NNH:MACE 224(95%CI 148-461)、心律失常396(95%CI 228-1,523)、PE 577(95%CI 309-4,311)、肺炎93(95%CI 69-141)。
- 次要分析(巢式病例对照和自身对照病例系列)结果与主要分析相似。
证据类型、等级与局限
- 证据类型:观察性研究(队列法主要分析,辅以巢式病例对照和自身对照病例系列)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为临床医生应遵循指南推荐,使用最低有效ICS剂量。
- 研究显示低剂量ICS短期使用与不良事件无关联,中高日剂量与心血管事件、PE和肺炎风险升高相关但绝对风险低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Inhaled corticosteroids (ICSs) are the cornerstone of asthma treatment and significantly improve morbidity and mortality. Adverse effects of oral corticosteroids are well documented, but less is known about ICS. Objectives: The aim of this study was to determine the risk of adverse effects from short-term ICS use in people with asthma. Methods: We conducted observational studies in adults with asthma using two different United Kingdom nationwide datasets: Clinical Practice Research Datalink Aurum and Clinical Practice Research Datalink GOLD. The exposure was incident ICS; the outcomes were a major adverse cardiac event (MACE), arrhythmia, pulmonary embolism (PE), and pneumonia over 12 months. Our main analyses used a cohort method with stabilized inverse probability treatment weighting to balance confounding between exposed and unexposed patients. Secondary analyses included nested case-control studies and self-controlled case series. ICS use was treated as both a categorical and a continuous variable. Absolute risk was estimated using weighted flexible parametric models. Measurements and Main Results: Among 162,202 patients in our main cohort, there was an association with all outcomes at the medium daily ICS dose or higher (hazard ratios [HRs] at 201-599 μg: MACE, 2.63 [95% confidence interval (CI), 1.66-4.15]; arrhythmia, 2.21 [95% CI, 1.60-3.04]; PE, 2.10 [95% CI, 1.37-3.22]; and pneumonia, 2.25 [95% CI, 1.77-2.85]; HRs at ≥600 μg: MACE, 4.63 [95% CI, 2.62-8.17]; arrhythmia, 2.91 [95% CI, 1.72-4.91]; PE, 3.32 [95% CI, 1.69-6.50]; and pneumonia, 4.09 [95% CI, 2.98-5.60]). There were no associations with lower doses of ICSs. Secondary analyses produced similar results. The number needed to harm using 12 months of ICS at 201 to 599 μg was as follows: MACE, 473 (95% CI, 344-754); arrhythmia, 567 (95% CI, 395-1,006); PE, 1,221 (95% CI, 744-3,388); and pneumonia, 230 (95% CI, 177-327). The number needed to harm using ICS at ≥600 μg was as follows: MACE, 224 (95% CI, 148-461); arrhythmia, 396 (95% CI, 228-1,523); PE, 577 (95% CI, 309-4,311); and pneumonia, 93 (95% CI, 69-141). Conclusions: Short-term use of low-dose ICS was not associated with adverse effects. Moderate to high daily ICS doses were associated with an increased risk, but low frequencies, of cardiovascular events, PE, and pneumonia. It is important for clinicians to adhere to guideline recommendations to use the lowest effective ICS dose.
参考来源
- Bloom CI, Yang F, Hubbard R, et al. Association of Dose of Inhaled Corticosteroids and Frequency of Adverse Events. Am J Respir Crit Care Med. 2025. PMID: 39088770. doi:10.1164/rccm.202402-0368OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。